Atlas Lauren Y, Wielgosz Joseph, Whittington Robert A, Wager Tor D
Department of Psychology, New York University, 6 Washington Place, New York, NY, 10003, USA,
Psychopharmacology (Berl). 2014 Mar;231(5):813-23. doi: 10.1007/s00213-013-3296-1. Epub 2013 Oct 6.
Psychological processes such as expectancy, attention, and affect directly influence clinical outcomes. These factors are grouped together as "nonspecific" factors, or placebo effects, in the medical literature, and their individual contributions are rarely considered. The pain-reducing effects of analgesic treatments may reflect changes in these psychological factors, rather than pure drug effects on pain. Furthermore, drug effects may not be isolated by drug vs. placebo comparisons if drugs interact with relevant psychological processes.
We sought to determine whether the analgesic effects of opioid and placebo treatment are mediated by changes in attention, expectancy, or affect.
We crossed intravenous administration of a potent opioid analgesic, remifentanil, with information about drug delivery (treatment expectancy or placebo) using a balanced placebo design. We measured drug and treatment expectancy effects on pain, attention, and responses to emotional images. We also examined interactions with cue-based expectations about noxious stimulation or stimulus expectancy.
Pain was additively influenced by treatment expectancy, stimulus expectancy, and drug concentration. Attention performance showed a small but significant interaction between drug and treatment expectancy. Finally, remifentanil enhanced responses to both positive and negative emotional images.
The pain-relieving effects of opioid drugs are unlikely to be mediated by changes in threat or affective processing. Standard open-label opioid administration influences multiple clinically relevant cognitive and emotional processes. Psychological factors can combine with drug effects to influence multiple outcomes in distinct ways. The influence of specific psychological factors should be considered when developing and testing pharmacological treatments.
诸如期望、注意力和情感等心理过程会直接影响临床结果。在医学文献中,这些因素被归为“非特异性”因素或安慰剂效应,而它们各自的作用很少被考虑。镇痛治疗的止痛效果可能反映了这些心理因素的变化,而非单纯药物对疼痛的作用。此外,如果药物与相关心理过程相互作用,那么通过药物与安慰剂对比可能无法分离出药物效应。
我们试图确定阿片类药物和安慰剂治疗的镇痛效果是否由注意力、期望或情感的变化介导。
我们采用平衡安慰剂设计,将强效阿片类镇痛药瑞芬太尼的静脉给药与关于药物给药的信息(治疗期望或安慰剂)进行交叉。我们测量了药物和治疗期望对疼痛、注意力以及对情感图像反应的影响。我们还研究了与基于线索的对有害刺激的期望或刺激期望的相互作用。
疼痛受到治疗期望、刺激期望和药物浓度的累加影响。注意力表现显示出药物与治疗期望之间存在微小但显著的相互作用。最后,瑞芬太尼增强了对正面和负面情感图像的反应。
阿片类药物的止痛效果不太可能由威胁或情感加工的变化介导。标准的开放标签阿片类药物给药会影响多个临床相关的认知和情感过程。心理因素可与药物效应相结合,以不同方式影响多个结果。在开发和测试药物治疗时应考虑特定心理因素的影响。